ASSESSMENT OF THE HYPOLIPIDEMIC EFFECT OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH A COMBINATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION

Authors:

Abstract:

The urgency of the problem of chronic obstructive pulmonary disease, in addition to the increase in morbidity and mortality, is also due to comorbidity, in particular with arterial hypertension, which increases the risk of cardiovascular events. The state of lipid metabolism is of particular importance in this context. The aim of the study was to study the dynamics of lipid metabolism according to the results of antihypertensive therapy in patients with a combination of chronic obstructive pulmonary disease and arterial hypertension. 58 patients with chronic obstructive pulmonary disease and arterial hypertension were examined without gender differences. Arterial hypertension was recorded at blood pressure ≥140/90 mmHg. All patients had grade 2 hypertension. A triple combination of perindopril, indapamide and amlodipine, was prescribed as an antihypertensive drug in doses of 10+2.5+10 and 5+1.25+5 mg. Statins were not included in the treatment regimen for both obstructive pulmonary disease and arterial hypertension. Systolic and dystolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol were determined. The results of the study showed the high effectiveness of antihypertensive therapy, regardless of the category of patients, as well as its pleiotropic effect in the form of positive dynamics of the atherogenic blood lipid fraction.

Keywords:

chronic obstructive pulmonary disease hypertension antihypertensive therapy lipid metabolism patients of category B patients of category E

References:

1. Andre S, Conde B, Fragoso E, Boleo-Tome JP, Areias V, Cardoso J; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Cronica. COPD and Cardiovascular Disease. Pulmonology. 2019 May-Jun; 25(3):168-176. 2. Arora S, Jain R, Mohan A, Tiwari P, Guleria R. Lipid Profile Status in Chronic Obstructive Pulmonary Disease and its Association with Disease Severity. Int J Respir Pulm Med 2018; 5:089. doi.org/10.23937/2378-3516/1410089.
2. Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond). 2022 Mar 3; 136(6):405-423.
3. Chen H, Li Z, Dong L, Wu Y, Shen H, Chen Z. Lipid metabolism in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019 May 13; 14: 1009-1018. doi: 10.2147/COPD.S196210.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for Prevention, Diagnosis and Management of COPD. [Updated 2023]. [Assessed September 12, 2022]. https://goldcopd.org/2022-gold-reports-2 .
5. Jonassen TM, Bjorvatn B, Saeed S, M Eagan T, Lehmann S.Impact of obstructive lung disease and sleep apnea symptoms on cardiovascular risk and all-cause mortality: insights from a community-dwelling cohort. Sleep Breath.2026 Jan 5; 30(1):17. doi: 10.1007/s11325-025-03564-0.
6. Kim JJ, Kim DB, Jang SW, Cho EJ, Chang K, Baek SH, et al. Relationship between airflow obstruction and coronary atherosclerosis in asymptomatic individuals: evaluation by coronary CT angiography. Int. J Cardiovascular Imaging.2018 Apr; 34 (4):641-648. doi: 10.1007/s10554-017-1259-z.
7. Li M, Xu B, Yu H, Wan Y, Zhu Z, Luo P, et al. Associations between serum lipid profiles and the incidence of chronic obstructive pulmonary disease in the UK Biobank. Health Popul Nutr.2025 Aug 6; 44(1):281. doi: 10.1186/s41043-025-01026-7.
8. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7; 45(38):3912-4018. doi: 10.1093/eurheartj/ehae178.
9. Park JH, Mun S, Choi DP, Lee JY, Kim HC. Association between high-density lipoprotein cholesterol level and pulmonary function in healthy Korean adolescents: the JS high school study. BMC Pulm Med. 2017 Dec 11;17(1):190. doi: 10.1186/s12890-017-0548-6.
10. Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, et al. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study. Chest. 2021 Oct; 160(4):1255-1270. doi: 10.1016/j.chest.2021.05.025.
11. Wen X, Wu X, Deng Z, Wu F, Yang H, Xiao S, et al. The Nonlinear Relationship Between High-Density Lipoprotein and Changes in Pulmonary Structure Function and Pulmonary Function in COPD Patients in China. Int J Chron Obstruct Pulmon. Dis. 2024 Aug 6;19:1801-1812.doi: 10. 2147/COPD. S467976.
12. Yeh JJ, Lai MC, Yang YC, Hsu CY, Kao CH. Relationships Between Bronchodilators, Steroids, Antiarrhythmic Drugs, Antidepressants, and Benzodiazepines and Heart Disease and Ischemic Stroke in Patients With Predominant Bronchiectasis and Asthma. Front Cardiovasc Med. 2022 Feb 17; 9:797623. doi :10.3389/fcvm.2022.797623.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 145-149
УДК 616.233-002; 616.12-008.331.1:616.24-008.4

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-145-149